MISSISSAUGA, ON, June 22, 2022 /CNW/ – Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or the “Company“) today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company’s management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of Ernst & Young LLP as the Company’s auditors and approving the unallocated shares, rights and other entitlements under the Company’s share purchase plan. A total of 14.2 million shares, representing 55.9% of the total shares outstanding were represented in person or by proxy at the meeting. The Board of Directors (the “Board”) of the Company is now comprised as follows:
% shares voted for
% shares withheld
Company founder and long-standing director Dr. John Mull decided not to stand for re-election to the Company’s Board.
Craig Mull, Interim CEO commented, “As the founder and former CEO of Cipher, Dr. Mull has been instrumental in the growth of the Company. During his tenure, Dr. Mull helped develop, and played a critical role obtaining FDA and Health Canada approval for three products, including the Cipher’s isotrentinoin portfolio. Under his stewardship, Cipher developed some of the leading acne products in North America. Dr. Mull also played a key role helping to capitalize the Company, which set it on the path for success. On behalf of the Board, I would like to thank him for his years of service and wish him well with his real estate development business and other future endeavours.”
“It has been extremely rewarding to witness and be a part of the evolution of Cipher since it was spun out of CML Healthcare in 2004. Today, the Company has a stable foundation with solid distribution and supply agreements in place in addition to a disciplined cost structure – positioning it well to continue to accelerate growth and drive shareholder value. As a continuing significant shareholder of the Company, I look forward to monitoring the Company’s future development.” noted Dr. John Mull.
Final voting results of all matters voted on at the meeting will be made available on SEDAR at www.sedar.com.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements regarding the future of the Company’s business as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective”, “hope” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, the extent and impact of the coronavirus (COVID-19) outbreak on our business including any impact on our contract manufacturers and other third party service providers, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process is highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; requirements for additional capital to fund future operations; products in Canada may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the U.S., Canada or any other jurisdictions and current uncertainty surrounding health care regulation in the U.S.; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; limited reimbursement for products by government authorities and third-party payor policies; products may not be included on list of drugs approved for use in hospitals; hospital customers may make late payments or not make any payments; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which we operate; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; legacy risks from operations conducted in the U.S.; compliance with privacy and security regulation; our policies regarding returns, allowances and chargebacks may reduce revenues; certain current and future regulations could restrict our activities; additional regulatory burden and controls over financial reporting; reliance on third parties to perform certain services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; litigation in the pharmaceutical industry concerning the manufacture and supply of novel and generic versions of existing drugs; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; we do not currently intend to pay dividends; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up.
We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the “Risk Factors” section of the Company’s Annual Information Form for the year ended December 31, 2021, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.
SOURCE Cipher Pharmaceuticals Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2022/22/c1023.html
EV makers are facing high costs and supply chain issues. It would be easy to cut corners at the expense of sustainable material sourcing.
Chinese battery giant CATL will start mass production next year of its latest generation product, with greater efficiency that lets electric cars drive longer distances on each charge, the company said on Thursday. The world’s biggest battery maker is scrambling to retain its top position against competition from rivals such as BYD, which will soon start supplying batteries to Tesla. CATL’s new battery, called Qilin, will boost volume utilisation rate to 72%, the world’s highest, versus 50% for its first generation launched in 2019, the firm said, and increase the battery system’s energy density to 255 Wh/kg.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications for [225Ac]-FPI-2059 (FPI-2059) and the corresponding imaging analogue [111In]-FPI-2058 (FPI-2058). FPI-2059 is a targeted alpha therapy (TAT) designed to use a small molecule to target and deliver actini
As it announced a CEO change, Mars revealed its sales have doubled over the last decade
Burry’s not bullish. But he’s beginning to nibble.
These phenomenal stocks are begging to be bought following a bear market decline in the Nasdaq and S&P 500.
Harding Loevner, an investment management firm, published its “Global Equity Fund” first-quarter 2022 investor letter – a copy of which can be downloaded here. The Global Equity Composite fell 12.4% gross of fees, well beyond the 5.3% decline of the MSCI All Country World Index. The portfolio’s concentration in expensive stocks, a hazard of its commitment […]
These veteran companies have attractive dividend yields, yet both recently underwent business transformations.
The rapidly rising interest rate environment proved to be a huge headwind for the artificial intelligence lender Upstart (NASDAQ: UPST) in the first quarter of 2022. As the Federal Reserve began raising its benchmark overnight lending rate, the federal funds rate, the market — sensing a newly hawkish Fed — quickly drove up other short-term rates. This put pressure on loan demand and Upstart’s overall business model.
For dividend growth investors the market drop hasn’t been as severe and they can sleep better at night knowing that their passive income will almost certainly grow, regardless of what happens in the market. This is especially true for those who are invested in dividend growth stocks that have earned the title Dividend King. If you are seeking to grow your passive income and wealth over the long haul, you might want to take a closer look at any of these five Dividend Kings that look like great buys at the moment.
Powell is being bullied by the stock and bond markets into raising interest rates more quickly and will send the economy into recession.
Rogers knows a thing or two about making money in turbulent times.
(Bloomberg) — With fervor in markets receding, investors will need to critically focus on fundamentals and security selection to ride out the turbulence, Abby Joseph Cohen said.Most Read from BloombergThe World’s Bubbliest Housing Markets Are Flashing Warning SignsJuul Soon to Be Ordered Off the Market by FDA, WSJ ReportsStocks Snap Rally as Recession Fears Mount: Markets WrapSwitzerland Imports Russian Gold for First Time Since WarPowell Says Soft Landing ‘Very Challenging;’ Recession Possible
Over the past eight years, Microsoft (NASDAQ: MSFT) transformed itself from an aging legacy software company into a high-growth cloud giant. Satya Nadella, who took the helm as Microsoft’s third CEO in early 2014, spearheaded the company’s "mobile first, cloud first" initiative which converted a large portion of its desktop software into mobile apps and cloud services. Between fiscal 2014 and fiscal 2021, which ended last June, Microsoft’s annual cloud revenues rose from just 5% of its top line in fiscal 2014 to 41% in fiscal 2021.
With gasoline prices through the roof at record highs, inflation running at 40-year record levels, and last year’s bullish stock market turn down into a genuine bear, it’s no wonder that the financial and economic worlds are looking like reruns of ‘That 70s Show.’ Market watchers remember that the bad times of the late 70s and early 80s were tamed only when Fed Chair Paul Volker sparked a recession with near-20% interest rates – and for investors under 45, just take note that Q1 this year saw a
Shipping giant FedEx is set to report Q4 earnings on Thursday after the closing bell with analysts expecting a 37% rise.
The clouds are gathering on the global economic horizon. In a clear sign that the good times of easy money are well and truly over, last week three major central banks – the US Federal Reserve, the Bank of England, and the Swiss National Bank – all enacted interest rate increases. For the Federal Reserve, it was a 0.75% hike, the largest bump since 1994, in reaction to news that the year-over-year inflation rate had reached a 40+ year high of 8.6%. So, how can investors ride out this hostile env
Wells Fargo Head of Macro Strategy Mike Schumacher joins Yahoo Finance Live to discuss inflationary pressures, Treasury yields, rate hikes, bond market action, and the outlook for the Fed as Fed Chair Powell testifies before Congress.
(Bloomberg) — Contemporary Amperex Technology Co. Ltd. unveiled an electric-car battery it said has a range of over 1,000 kilometers (620 miles) on a single charge and is 13% more powerful than one planned by Tesla Inc., a major customer. Most Read from BloombergThe World’s Bubbliest Housing Markets Are Flashing Warning SignsElon Musk Says New Tesla Plants Are ‘Money Furnaces’ Losing BillionsJuul Soon to Be Ordered Off the Market by FDA, WSJ ReportsPowell Says Soft Landing ‘Very Challenging;’ R
The purchases were made over the past week and cost about $529 million, Berkshire said in a regulatory filing on Wednesday. Following the purchases, Berkshire now owns about 152.7 million Occidental shares worth about $8.52 billion based on Occidental stock’s Wednesday close, which is down over 21% since it touched its year’s high in May. However, Occidental’s share prices are currently up over 90% this year, after more than doubling, as they benefited from Berkshire’s purchases and rising oil prices following Russia’s invasion of Ukraine.